The deleterious effects of plastic debris on the marine environment were reviewed by bringing tog... more The deleterious effects of plastic debris on the marine environment were reviewed by bringing together most of the literature published so far on the topic. A large number of marine species is known to be harmed and/or killed by plastic debris, which could jeopardize their survival, especially since many are already endangered by other forms of anthropogenic activities. Marine animals are mostly affected through entanglement in and ingestion of plastic litter. Other less known threats include the use of plastic debris by ''invader'' species and the absorption of polychlorinated biphenyls from ingested plastics. Less conspicuous forms, such as plastic pellets and ''scrubbers'' are also hazardous. To address the problem of plastic debris in the oceans is a difficult task, and a variety of approaches are urgently required. Some of the ways to mitigate the problem are discussed.
One of the primary threats to ocean ecosystems from plastic pollution is ingestion by marine orga... more One of the primary threats to ocean ecosystems from plastic pollution is ingestion by marine organisms. Well-documented in seabirds, turtles, and marine mammals, ingestion by fish and sharks has received less attention until recently. We suggest that fishes of a variety of sizes attack drifting plastic with high frequency, as evidenced by the apparent bite marks commonly left behind. We examined 5518 plastic items from random plots on Kamilo Point, Hawai'i Island, and found 15.8% to have obvious signs of attack. Extrapolated to the entire amount of debris removed from the 15 km area, over 1.3 tons of plastic is attacked each year. Items with a bottle shape, or those blue or yellow in color, were attacked with a higher frequency. The triangular edges or punctures left by teeth ranged from 1 to 20 mm in width suggesting a variety of species attack plastic items. More research is needed to document the specific fishes and rates of plastic ingestion.
American Journal of Respiratory and Critical Care Medicine, 2010
Continuous positive airway pressure (CPAP) is the current treatment for patients with symptomatic... more Continuous positive airway pressure (CPAP) is the current treatment for patients with symptomatic obstructive sleep apnea (OSA). Its use for all subjects with sleep-disordered breathing, regardless of daytime symptoms, is unclear. This multicenter controlled trial assesses the effects of 1 year of CPAP treatment on blood pressure (BP) in nonsymptomatic, hypertensive patients with OSA. We evaluated 359 patients with OSA. Inclusion criteria consisted of an apnea-hypopnea index (AHI) greater than 19 hour(-1), an Epworth Sleepiness Scale score less than 11, and one of the following: under antihypertensive treatment or systolic blood pressure greater than 140 or diastolic blood pressure greater than 90 mm Hg. Patients were randomized to CPAP (n = 178) or to conservative treatment (n = 181). BP was evaluated at baseline and at 3, 6, and 12 months of follow-up. Mean (SD) values were as follows: age, 56 +/- 10 years; body mass index (BMI), 32 +/- 5 kg x m(-2); AHI, 45 +/- 20 hour(-1); and Epworth Sleepiness Scale score, 7 +/- 3. After adjusting for follow-up time, baseline blood pressure values, AHI, time with arterial oxygen saturation less than 90%, and BMI, together with the change in BMI at follow-up, CPAP treatment decreased systolic blood pressure by 1.89 mm Hg (95% confidence interval: -3.90, 0.11 mm Hg; P = 0.0654), and diastolic blood pressure by 2.19 mm Hg (95% confidence interval: -3.46, -0.93 mm Hg; P = 0.0008). The most significant reduction in BP was in patients who used CPAP for more than 5.6 hours per night. CPAP compliance was related to AHI and the decrease in Epworth Sleepiness Scale score. In nonsleepy hypertensive patients with OSA, CPAP treatment for 1 year is associated with a small decrease in BP. This effect is evident only in patients who use CPAP for more than 5.6 hours per night. Clinical trial registered with www.clinicaltrials.gov (NCT00127348).
The deleterious effects of plastic debris on the marine environment were reviewed by bringing tog... more The deleterious effects of plastic debris on the marine environment were reviewed by bringing together most of the literature published so far on the topic. A large number of marine species is known to be harmed and/or killed by plastic debris, which could jeopardize their survival, especially since many are already endangered by other forms of anthropogenic activities. Marine animals are mostly affected through entanglement in and ingestion of plastic litter. Other less known threats include the use of plastic debris by ''invader'' species and the absorption of polychlorinated biphenyls from ingested plastics. Less conspicuous forms, such as plastic pellets and ''scrubbers'' are also hazardous. To address the problem of plastic debris in the oceans is a difficult task, and a variety of approaches are urgently required. Some of the ways to mitigate the problem are discussed.
One of the primary threats to ocean ecosystems from plastic pollution is ingestion by marine orga... more One of the primary threats to ocean ecosystems from plastic pollution is ingestion by marine organisms. Well-documented in seabirds, turtles, and marine mammals, ingestion by fish and sharks has received less attention until recently. We suggest that fishes of a variety of sizes attack drifting plastic with high frequency, as evidenced by the apparent bite marks commonly left behind. We examined 5518 plastic items from random plots on Kamilo Point, Hawai'i Island, and found 15.8% to have obvious signs of attack. Extrapolated to the entire amount of debris removed from the 15 km area, over 1.3 tons of plastic is attacked each year. Items with a bottle shape, or those blue or yellow in color, were attacked with a higher frequency. The triangular edges or punctures left by teeth ranged from 1 to 20 mm in width suggesting a variety of species attack plastic items. More research is needed to document the specific fishes and rates of plastic ingestion.
American Journal of Respiratory and Critical Care Medicine, 2010
Continuous positive airway pressure (CPAP) is the current treatment for patients with symptomatic... more Continuous positive airway pressure (CPAP) is the current treatment for patients with symptomatic obstructive sleep apnea (OSA). Its use for all subjects with sleep-disordered breathing, regardless of daytime symptoms, is unclear. This multicenter controlled trial assesses the effects of 1 year of CPAP treatment on blood pressure (BP) in nonsymptomatic, hypertensive patients with OSA. We evaluated 359 patients with OSA. Inclusion criteria consisted of an apnea-hypopnea index (AHI) greater than 19 hour(-1), an Epworth Sleepiness Scale score less than 11, and one of the following: under antihypertensive treatment or systolic blood pressure greater than 140 or diastolic blood pressure greater than 90 mm Hg. Patients were randomized to CPAP (n = 178) or to conservative treatment (n = 181). BP was evaluated at baseline and at 3, 6, and 12 months of follow-up. Mean (SD) values were as follows: age, 56 +/- 10 years; body mass index (BMI), 32 +/- 5 kg x m(-2); AHI, 45 +/- 20 hour(-1); and Epworth Sleepiness Scale score, 7 +/- 3. After adjusting for follow-up time, baseline blood pressure values, AHI, time with arterial oxygen saturation less than 90%, and BMI, together with the change in BMI at follow-up, CPAP treatment decreased systolic blood pressure by 1.89 mm Hg (95% confidence interval: -3.90, 0.11 mm Hg; P = 0.0654), and diastolic blood pressure by 2.19 mm Hg (95% confidence interval: -3.46, -0.93 mm Hg; P = 0.0008). The most significant reduction in BP was in patients who used CPAP for more than 5.6 hours per night. CPAP compliance was related to AHI and the decrease in Epworth Sleepiness Scale score. In nonsleepy hypertensive patients with OSA, CPAP treatment for 1 year is associated with a small decrease in BP. This effect is evident only in patients who use CPAP for more than 5.6 hours per night. Clinical trial registered with www.clinicaltrials.gov (NCT00127348).
Uploads
Papers by Camila Peña